08:30 AM EDT, 06/04/2024 (MT Newswires) -- Viking Therapeutics ( VKTX ) reported "positive" 52-week data from its phase 2b study of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis, or NASH.

The study showed significant reductions in liver fat and improvements in liver histology, the company said.

VK2809-treated patients met secondary endpoints, showing higher rates of NASH resolution, fibrosis improvement, and combined NASH resolution and fibrosis improvement compared to placebo, Viking Therapeutics ( VKTX ) said.

VK2809 demonstrated safety and tolerability, with mostly mild or moderate adverse events, according to the company.

Viking shares rose by more than 5% in premarket trading.

Price: 65.48, Change: +3.21, Percent Change: +5.15